mRNA: A promising platform for cancer immunotherapy

Byoungjae Kong, Yelee Kim, Eun Hye Kim, Jung Soo Suk, Yoosoo Yang

Research output: Contribution to journalReview articlepeer-review

Abstract

Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

Original languageEnglish (US)
Article number114993
JournalAdvanced Drug Delivery Reviews
Volume199
DOIs
StatePublished - Aug 2023

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'mRNA: A promising platform for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this